Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.

Guardado en:

Detalles Bibliográficos
Autores principales:	Sue Ann Costa Clemens, Pedro M. Folegatti, Katherine R. W. Emary, Lily Yin Weckx, Jeremy Ratcliff, Sagida Bibi, Ana Verena De Almeida Mendes, Eveline Pipolo Milan, Ana Pittella, Alexandre V. Schwarzbold, Eduardo Sprinz, Parvinder K. Aley, David Bonsall, Christophe Fraser, Michelle Fuskova, Sarah C. Gilbert, Daniel Jenkin, Sarah Kelly, Simon Kerridge, Teresa Lambe, Natalie G. Marchevsky, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Peter Simmonds, Tanya Golubchik, Merryn Voysey, Andrew J. Pollard, the AMPHEUS Project, Oxford COVID Vaccine Trial Team
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/2174b542d59f4531bfbfd908fa719572
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2174b542d59f4531bfbfd908fa719572
record_format	dspace
spelling	oai:doaj.org-article:2174b542d59f4531bfbfd908fa7195722021-12-02T18:37:28ZEfficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil10.1038/s41467-021-25982-w2041-1723https://doaj.org/article/2174b542d59f4531bfbfd908fa7195722021-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25982-whttps://doaj.org/toc/2041-1723Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.Sue Ann Costa ClemensPedro M. FolegattiKatherine R. W. EmaryLily Yin WeckxJeremy RatcliffSagida BibiAna Verena De Almeida MendesEveline Pipolo MilanAna PittellaAlexandre V. SchwarzboldEduardo SprinzParvinder K. AleyDavid BonsallChristophe FraserMichelle FuskovaSarah C. GilbertDaniel JenkinSarah KellySimon KerridgeTeresa LambeNatalie G. MarchevskyYama F. MujadidiEmma PlestedMaheshi N. RamasamyPeter SimmondsTanya GolubchikMerryn VoyseyAndrew J. Pollardthe AMPHEUS ProjectOxford COVID Vaccine Trial TeamNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Sue Ann Costa Clemens Pedro M. Folegatti Katherine R. W. Emary Lily Yin Weckx Jeremy Ratcliff Sagida Bibi Ana Verena De Almeida Mendes Eveline Pipolo Milan Ana Pittella Alexandre V. Schwarzbold Eduardo Sprinz Parvinder K. Aley David Bonsall Christophe Fraser Michelle Fuskova Sarah C. Gilbert Daniel Jenkin Sarah Kelly Simon Kerridge Teresa Lambe Natalie G. Marchevsky Yama F. Mujadidi Emma Plested Maheshi N. Ramasamy Peter Simmonds Tanya Golubchik Merryn Voysey Andrew J. Pollard the AMPHEUS Project Oxford COVID Vaccine Trial Team Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
description	Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.
format	article
author	Sue Ann Costa Clemens Pedro M. Folegatti Katherine R. W. Emary Lily Yin Weckx Jeremy Ratcliff Sagida Bibi Ana Verena De Almeida Mendes Eveline Pipolo Milan Ana Pittella Alexandre V. Schwarzbold Eduardo Sprinz Parvinder K. Aley David Bonsall Christophe Fraser Michelle Fuskova Sarah C. Gilbert Daniel Jenkin Sarah Kelly Simon Kerridge Teresa Lambe Natalie G. Marchevsky Yama F. Mujadidi Emma Plested Maheshi N. Ramasamy Peter Simmonds Tanya Golubchik Merryn Voysey Andrew J. Pollard the AMPHEUS Project Oxford COVID Vaccine Trial Team
author_facet	Sue Ann Costa Clemens Pedro M. Folegatti Katherine R. W. Emary Lily Yin Weckx Jeremy Ratcliff Sagida Bibi Ana Verena De Almeida Mendes Eveline Pipolo Milan Ana Pittella Alexandre V. Schwarzbold Eduardo Sprinz Parvinder K. Aley David Bonsall Christophe Fraser Michelle Fuskova Sarah C. Gilbert Daniel Jenkin Sarah Kelly Simon Kerridge Teresa Lambe Natalie G. Marchevsky Yama F. Mujadidi Emma Plested Maheshi N. Ramasamy Peter Simmonds Tanya Golubchik Merryn Voysey Andrew J. Pollard the AMPHEUS Project Oxford COVID Vaccine Trial Team
author_sort	Sue Ann Costa Clemens
title	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
title_short	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
title_full	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
title_fullStr	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
title_full_unstemmed	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
title_sort	efficacy of chadox1 ncov-19 (azd1222) vaccine against sars-cov-2 lineages circulating in brazil
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2174b542d59f4531bfbfd908fa719572
work_keys_str_mv	AT sueanncostaclemens efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT pedromfolegatti efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT katherinerwemary efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT lilyyinweckx efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT jeremyratcliff efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT sagidabibi efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT anaverenadealmeidamendes efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT evelinepipolomilan efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT anapittella efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT alexandrevschwarzbold efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT eduardosprinz efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT parvinderkaley efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT davidbonsall efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT christophefraser efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT michellefuskova efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT sarahcgilbert efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT danieljenkin efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT sarahkelly efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT simonkerridge efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT teresalambe efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT nataliegmarchevsky efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT yamafmujadidi efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT emmaplested efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT maheshinramasamy efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT petersimmonds efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT tanyagolubchik efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT merrynvoysey efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT andrewjpollard efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT theampheusproject efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil AT oxfordcovidvaccinetrialteam efficacyofchadox1ncov19azd1222vaccineagainstsarscov2lineagescirculatinginbrazil
_version_	1718377786971783168

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Ejemplares similares